Basel, 17 March 2023: Medartis Holding AG (SIX: MED), an orthopaedic company specialising in head and extremity surgery, today announced the successful completion of a small capital increase of CHF 30 million in a private placement to finance an additional stake in Keri Medical SA and for general corporate purposes.

As part of its growth strategy, Medartis announced at the publication of its 2022 annual results on Tuesday 14 March that it had signed an agreement to increase its stake in Keri Medical SA to 47% through the purchase of an additional 18% stake for approximately CHF 18 million. 476 190 newly issued shares, representing 4% of the total share capital, were sold in a private placement to a selected number of institutional investors.

Dirk Kirsten, CFO Medartis, comments: “Following the publication of our 2022 annual results, we received positive signals from investors and shareholders. We decided to take advantage of this opportunity to expand the free float of our share.”

These shares will be traded on the SIX Swiss Exchange from 23 March 2023. The new shares were issued from existing authorised capital at a price of CHF 63.00 per share each, which represents a discount of 4.7% to volume weighted average price of the Medartis shares on 14 and 15 March 2023.

Your contact:
Medartis Corporate Communications
Investor contact:
Media contact:
+41 61 633 37 34 / +41 61 633 37 36

About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world’s leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs approx. 860 Page 2 of 2 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best-in-class service. For more information, please visit

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein or of the views given or implied, and accordingly no reliance should be placed on.